DoW Vision, Translational Research Award

Key Facts

Status: Open

Posted date: May 3, 2026

Opportunity ID: 362186

Opportunity number: HT942526VRPTRA

Opportunity category: Discretionary

Agency name: Dept. of the Army -- USAMRAA

Agency code: DOD-AMRAA

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Grant
Category of Funding Activity
  • Science and Technology and other Research and Development
Eligible Applicants
  • Unrestricted
Tools
Categories (use these for quoted searches)
  • agency_code:dod_amraa
  • category_of_funding_activity:science_and_technology_and_other_research_and_development
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:unrestricted
  • funding_instrument_type:grant
  • opportunity_category:discretionary
  • status:open
Description

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Translational Research Award (TRA) supports translational research that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The TRA may be used to support preclinical studies, clinical research or a pilot clinical trial, but not a full-scale clinical trial. Research must align with at least one of the FY26 VRP Focus Areas. Distinctive Features: · If developing new drugs or device(s), the research team must include expertise in the regulatory approval process. · The TRA includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. · Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, Personnel and Post-Award Transition Plan. · Programmatic review criteria include adherence to the intent of the TRA, contribution to the VRP portfolio, relative impact and relevance to military health. · The VRP may share FY26 TRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann

DoW Vision, Translational Research Award
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Translational Research Award (TRA) supports translational research that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The TRA may be used to support preclinical studies, clinical research or a pilot clinical trial, but not a full-scale clinical trial. Research must align with at least one of the FY26 VRP Focus Areas. Distinctive Features: · If developing new drugs or device(s), the research team must include expertise in the regulatory approval process. · The TRA includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. · Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, Personnel and Post-Award Transition Plan. · Programmatic review criteria include adherence to the intent of the TRA, contribution to the VRP portfolio, relative impact and relevance to military health. · The VRP may share FY26 TRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann
DoW Vision, Translational Research Award
Open
Dept. of the Army -- USAMRAA
Science and Technology and other Research and Development
Grant
Unrestricted
2026-05-03